TELA Bio (TELA) to Release Earnings on Thursday

TELA Bio (NASDAQ:TELA) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. TELA Bio has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

TELA Bio (NASDAQ:TELA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.06). The firm had revenue of $16.09 million during the quarter, compared to analysts’ expectations of $19.00 million. TELA Bio had a negative return on equity of 252.57% and a negative net margin of 65.04%. During the same quarter last year, the business earned ($0.46) earnings per share. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Stock Up 2.5 %

TELA Bio stock opened at $2.92 on Wednesday. TELA Bio has a one year low of $2.30 and a one year high of $7.84. The stock has a fifty day moving average of $2.65 and a 200 day moving average of $4.02. The company has a debt-to-equity ratio of 14.22, a quick ratio of 2.52 and a current ratio of 3.41. The stock has a market cap of $72.15 million, a PE ratio of -1.70 and a beta of 0.97.

Wall Street Analysts Forecast Growth

TELA has been the subject of a number of research reports. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Piper Sandler decreased their target price on TELA Bio from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and set a $12.00 price target on shares of TELA Bio in a report on Friday, October 4th. Finally, JMP Securities decreased their price objective on TELA Bio from $15.00 to $12.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th.

Insider Activity

In other TELA Bio news, CTO Paul Talmo purchased 22,222 shares of the business’s stock in a transaction on Thursday, October 24th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $49,999.50. Following the purchase, the chief technology officer now owns 91,082 shares of the company’s stock, valued at approximately $204,934.50. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Roberto Cuca bought 64,444 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $144,999.00. Following the completion of the transaction, the chief financial officer now owns 155,388 shares in the company, valued at $349,623. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CTO Paul Talmo bought 22,222 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The shares were bought at an average cost of $2.25 per share, with a total value of $49,999.50. Following the completion of the purchase, the chief technology officer now directly owns 91,082 shares of the company’s stock, valued at $204,934.50. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 182,220 shares of company stock worth $409,995 in the last three months. Company insiders own 6.00% of the company’s stock.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.